|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
RAGE has been extensively implicated in inflammatory states such as atherosclerosis, but the role of S100A12 as its ligand is less clear.
|
19875725 |
2010 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Interestingly, the accelerated atherosclerosis could be prevented by RAS inhibition, or markedly reduced by RAGE blockade, probably through anti-inflammatory and antioxidative effects.
|
19939336 |
2009 |
|
Atherosclerosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In total, nine SNPs of RAGE were analyzed in individuals with and without type 2 diabetes in CODAM: a cohort study of diabetes and atherosclerosis, Maastricht.
|
18079485 |
2008 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Strategies to reduce the ligation of AGEs to their receptors such as agents which reduce AGE accumulation, soluble RAGE which acts as a competitive antagonist to the binding of AGEs to RAGE and genetic deletions of RAGE appear to attenuate diabetes associated atherosclerosis.
|
18473849 |
2008 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
LHGDN |
Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice.
|
18079965 |
2008 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The expression of RAGE is up-regulated in atherosclerotic plaques of diabetic animals, and the augmentation of atherosclerosis in diabetic mice is inhibited by the competition of RAGE.
|
18089449 |
2008 |
|
Atherosclerosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The -374T/A polymorphism of the Receptor for Advanced Glycation End products (RAGE) may exert a protective effect toward the development of atherosclerosis.
|
18279705 |
2008 |
|
Atherosclerosis
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients.
|
18777492 |
2008 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
|
17761193 |
2007 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
LHGDN |
RAGE axis: Animal models and novel insights into the vascular complications of diabetes.
|
15155381 |
2004 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The receptor for advanced glycation end products (RAGE) is thought to play a critical role in diabetic atherosclerosis.
|
15547674 |
2004 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Studies in rodent models of diabetes suggest that blockade or genetic modification of RAGE suppress diabetes-associated progression of atherosclerosis, exaggerated neointimal expansion consequent to acute arterial injury, and cardiac dysfunction.
|
16305050 |
2004 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Amelioration of atherosclerosis in these diabetic/atherosclerotic animals by soluble RAGE occurred in the absence of changes in plasma lipids or glycemia, emphasizing the contribution of a lipid- and glycemia-independent mechanism(s) to atherogenesis, which we postulate to be interaction of RAGE with its ligands.
|
10082470 |
1999 |